Astellas also revealed today that it is terminating the development of ASP2390, a DNA vaccine for house dust mite-induced allergic rhinitis, and GITR agonist antibody ASP1951 for cancer – both ...

Astellas is preparing a significant shake-up of its top-tier roles, including transforming its chief medical officer into a new R&D position and ushering out its current chief scientific officer ...

On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to reach the finish line. Now, following a review of its pipeline ...

China detains South Korean on suspicion of espionage Worldcategory· October 29, 2024 The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of gastric cancer ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

La medicina Prograf, del laboratorio Astellas Pharma, se receta después de trasplantes de corazón, hígado, riñones o pulmones. Por su parte, Astagraf XL, también de Astellas, se receta luego ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener Astellas Pharma ...

La entidad que agrupa a 41 laboratorios principalmente de capitales extranjeros pero deja librado a cada firma la facultad de adherir a la iniciativa. Algunos de los laboratorios que forman parte ...

Under the agreement, Axcelead DDP will support Astellas’ targeted protein degrader discovery utilizing DegLead TM Platform and contribute to the generation of breakthrough new drug candidate ...

(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration accepted the revised supplemental New Drug Application or sNDA for IZERVAY (avacincaptad pegol ...